Actavis Inc (ACT): Today's Featured Drugs Laggard
(
) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.9%. By the end of trading, Actavis fell $1.64 (-1.3%) to $124.07 on light volume. Throughout the day, 1,148,148 shares of Actavis exchanged hands as compared to its average daily volume of 1,692,000 shares. The stock ranged in price between $123.30-$126.30 after having opened the day at $126.04 as compared to the previous trading day's close of $125.71. Other companies within the Drugs industry that declined today were:
(
), down 34.9%,
(
), down 25.2%,
(
), down 10.3% and
Bacterin International Holdings
(
), down 8.7%.
Actavis, Inc., an integrated specialty pharmaceutical company, engages in developing, manufacturing, marketing, selling, and distributing generic, branded generic, brand, biosimilar, and over-the-counter pharmaceutical products worldwide. Actavis has a market cap of $16.2 billion and is part of the health care sector. Shares are up 46.2% year to date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Actavis a buy, no analysts rate it a sell, and 6 rate it a hold.
TheStreet Ratings rates
Actavis
as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
- You can view the full Actavis Ratings Report.
On the positive front,
(
), up 24.6%,
(
), up 14.9%,
(
), up 12.0% and
(
), up 10.5% , were all gainers within the drugs industry with
(
) being today's featured drugs industry leader.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
null